HHS Office for Civil Rights launches tools to combat the US opioid epidemic

HHS Office for Civil Rights (OCR) has launched a host of initiatives to assist in alleviating the opioid epidemic while also implementing the 21st Century Cures Act.

The tools include efforts to secure sharing of information to families to prevent an overdose or mental health crisis. Additionally, the 21st Century Cure Act aims teach the researchers, patients and their families how the Health Insurance Portability and Accountability Act (HIPAA) protects privacy and improves health.

Actions include:

  • Creating two HIPAA websites that provide information on mental and behavioral health to professionals and consumers that will reorganize guidance and clarify what HIPAA covers.
  • New collaboration with partner agencies to identify and develop model programs for training of providers, patients and families on what is permitted in sharing patient health information.  
  • Updated guidance on HIPAA and research.
  • A working study to identify uses and disclosures under HIPAA of protected health information for research purposes.

“President Trump has mobilized the entire administration to address America’s opioid crisis,” said Roger Severino, Director of OCR. “HHS is using every tool at its disposal to help communities devastated by opioids including educating families and doctors on how they can share information to help save the lives of loved ones.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.